NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock Price

NRXPStock

$2.60−14.47%52W

Market Cap$112.57M

P/E—

PEG Ratio—

Div yield—

Beta2.03

NRXP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-5.91%

Price vs S&P 500 (4W)-19.65%

VGM Score33.07

Book Value / Share (Quarterly)$1.12

P/TBV (Annual)3.61x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.48

Price vs S&P 500 (YTD)-15.99%

Gross Margin (TTM)46.64%

Net Profit Margin (TTM)-691.81%

EPS (TTM)$-0.74

10-Day Avg Trading Volume0.66M

EPS Excl Extra (TTM)$-0.74

EPS (Annual)$-1.34

ROI (Annual)-221.67%

Gross Margin (Annual)58.78%

Cash / Share (Quarterly)$0.62

ROA (Last FY)-220.92%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-206.78%

Operating Margin (TTM)-666.74%

Cash Flow / Share (Annual)$-0.44

P/B Ratio15.19x

P/B Ratio (Quarterly)10.13x

Net Income / Employee (Annual)$-987,000

EV / Revenue (TTM)25.43x

Net Interest Coverage (TTM)-40.24x

ROA (TTM)-126.89%

EPS Incl Extra (Annual)$-1.34

Current Ratio (Annual)0.31x

Quick Ratio (Quarterly)0.79x

3-Month Avg Trading Volume0.86M

52-Week Price Return-14.47%

Revenue / Employee (TTM)$117,000

Tangible BV / Share (Quarterly)$-0.07

P/S Ratio (Annual)91.89x

Asset Turnover (Annual)0.09x

52-Week High$5.05

EPS Excl Extra (Annual)$-1.34

Tangible BV CAGR (5Y)-36.09%

26-Week Price Return4.00%

Quick Ratio (Annual)0.28x

13-Week Price Return-39.11%

Total Debt / Equity (Annual)1.42x

Current Ratio (Quarterly)0.86x

Enterprise Value$86.30M

Asset Turnover (TTM)0.18x

Book Value / Share Growth (5Y)-57.11%

Revenue / Employee (Annual)$42,200

Pretax Margin (Annual)-2336.49%

Cash / Share (Annual)$0.25

3-Month Return Std Dev62.64%

Net Income / Employee (TTM)$-809,700

ROE (Last FY)-536.56%

Net Interest Coverage (Annual)-14.18x

EPS Basic Excl Extra (Annual)$-1.34

Total Debt / Equity (Quarterly)1.42x

EPS Incl Extra (TTM)$-0.74

ROI (TTM)-172.32%

P/S Ratio (TTM)33.17x

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$0.11

Forward P/E3.89x

Price vs S&P 500 (52W)-30.01%

Year-to-Date Return-4.06%

5-Day Price Return-8.77%

EPS Normalized (Annual)$-1.34

ROA (5Y Avg)-351.92%

Net Profit Margin (Annual)-2336.49%

Month-to-Date Return-10.96%

Cash Flow / Share (TTM)$-0.50

EBITD / Share (Annual)$-1.04

Operating Margin (Annual)-1830.61%

LT Debt / Equity (Annual)0.38x

ROI (5Y Avg)-135.89%

LT Debt / Equity (Quarterly)0.38x

EPS Basic Excl Extra (TTM)$-0.74

P/B Ratio (Annual)10.13x

Pretax Margin (TTM)-691.81%

Book Value / Share (Annual)$1.12

Price vs S&P 500 (13W)-41.80%

Beta2.03x

Revenue / Share (TTM)$0.09

ROE (TTM)-195.76%

52-Week Low$1.62

vGradeF

mGradeC

vgmGradeD

NRXP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$0.13	-$0.24	-87.77%(-$0.11)
Q1 2026	May 15, 2026	-$0.11	-$0.04	+59.64%(+$0.07)
Q4 2025	Mar 23, 2026	-$0.08	$0.18	+329.13%(+$0.26)
Q3 2025	Nov 14, 2025	-$0.02	-$0.51	-2938.39%(-$0.49)
Q2 2025	Aug 18, 2025	-$0.23	-$0.98	-326.09%(-$0.75)

NRXP Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.18

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NRXPNRX Pharmaceuticals, Inc. Common Stock	F	—	C	33.2x	—	46.6%	—	$2.60
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About NRX Pharmaceuticals, Inc. Common Stock

NRX Pharmaceuticals is a clinical-stage pharmaceutical company developing small-molecule therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company has commercialized ZYESAMI (Aviptadil) for COVID-related respiratory failure and is advancing NRX-100/101, a sequential treatment regimen for bipolar depression in patients with acute suicidal ideation. Its pipeline targets unmet needs in critical care and psychiatry.

NRXP Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.15

Revenue estimate$1.29M

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

AVXLAnavex Life SciencesBiological Products
HUMAHumacyte, Inc. Common StockBiological Products
OTLKOutlook Therapeutics, Inc. Common StockBiological Products
VYGRVoyager Therapeutics, Inc. Common StockBiological Products
ENGNenGene Therapeutics Inc. Common StockBiological Products
WALDWaldencast plc Class A Ordinary ShareCosmetics & Toiletries
AMTXAemetis, Inc. (DE) Common StockIndustrial Chemicals
CLLSCellectis S.A. American Depositary SharesBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Buy

Consensus rating

52-Week Range

Low$1.62

High$5.05